Trial Profile
Phase II Study to Investigate the Treatment of Patients With NSCLC Stage IIIB and IV Without the Option of Surgery With a Combination of Cisplatin, Docetaxel and Bevacizumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Sep 2013
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 04 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Jun 2011 Integrated EudraCT record.
- 10 Jun 2011 New trial record